Profiling of EBV-Encoded microRNAs in EBV-Associated XXXX .

@entity1 @entity1075 @entity9058 @entity11216 @entity281 @entity9653 @entity2025 @entity4539 @entity405
@entity9653 -associated @entity9058 (EBV-HLH) is a life-threatening complication of @entity2025 . MicroRNAs (miRNAs) were small non-coding RNA, and EBV could encode miRNAs that are involved in the progression of @entity281 . However, the profiles of EBV-miRNAs in EBV-HLH were unknown. Here, we aimed to profile the expression of EBV-miRNAs in @entity1 with EBV-HLH by analyzing 44 known EBV-miRNAs, encoded within the BamHI fragment H rightward open reading frame 1 (BHRF1) and the BamHI-A region rightward transcript (BART), in plasma and cellular targets by real-time quantitative PCR. The study included 15 @entity1 with EBV-HLH, 15 @entity1 with @entity4539 ( @entity4539 ), and 15 healthy controls. @entity405 (+) T cells were found to be the cellular target of @entity2025 in EBV-HLH, while @entity1075 (+) B cells were infected with EBV in @entity4539 . We also found the greater levels of several miRNAs encoded by BART in EBV-HLH, compared to those in @entity4539 and healthy controls, whereas the levels of BHRF1 miRNAs were lower than those in @entity4539 . The profile and pattern of EBV-miRNAs in EBV-HLH indicated that EBV could display type II latency in EBV-HLH. Importantly, the level of plasma @entity11216 -BART16-1 continued decreasing during the whole chemotherapy, suggesting that plasma @entity11216 -BART16-1 could be a potential biomarker for monitoring EBV-HLH progression. The pathogenesis of EBV-HLH might be attributed to the abundance of EBV-miRNAs in EBV-HLH. These findings help elucidate the roles of EBV miRNAs in EBV-HLH, enabling the understanding of the basis of this disease and providing clues for its treatment.
